Latest Tanezumab Stories
A phase II clinical trial of the first new type of drug for musculoskeletal pain since aspirin shows that it significantly reduces knee pain in osteoarthritis, the most common osteoarthritis pain.
NEW YORK, July 19 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced, at the request of the U.S.
NEW YORK, June 23 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA).
SAN ANTONIO, Feb.